BioMarin Pharmaceutical Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | — | $4.39B | $605.4M |
| Jun 2022 | — | $4.50B | $619.8M |
| Sep 2022 | — | $4.57B | $761.5M |
| Dec 2022 | — | $4.60B | $724.5M |
| Mar 2023 | — | $4.66B | $580.1M |
| Jun 2023 | — | $4.78B | $694.4M |
| Sep 2023 | — | $4.90B | $785.4M |
| Dec 2023 | — | $4.95B | $755.1M |
| Mar 2024 | — | $5.07B | $747.0M |
| Jun 2024 | — | $5.29B | $972.2M |
| Sep 2024 | — | $5.41B | $675.4M |
| Dec 2024 | — | $5.66B | $942.8M |
| Mar 2025 | — | $5.79B | $1.05B |
| Jun 2025 | — | $6.03B | $1.21B |
| Sep 2025 | — | $6.06B | $1.25B |
| Dec 2025 | $597.2M | $6.09B | $1.31B |
| Mar 2026 | $1.43B | $6.21B | $2.22B |
| Jun 2026 | $3.53B | $6.32B | $874.0M |